DaVita Inc. (NYSE:DVA) Stock Rated “Moderate Buy” by Wall Street Brokerages

DaVita Inc. (NYSE:DVA) has received a consensus rating of “Moderate Buy” from the seven ratings firms that are covering the firm, MarketBeat reports. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $233.43.

DVA has been the topic of a number of research reports. Oppenheimer set a $220.00 price objective on DaVita in a report on Friday, August 7th. Wall Street Zen upgraded DaVita from a “hold” rating to a “buy” rating in a research report on Saturday. Weiss Ratings raised DaVita from a “hold (c+)” rating to a “buy (b-)” rating in a report on Friday, October 9th. Zacks Research downgraded DaVita from a “strong-buy” rating to a “hold” rating in a report on Monday, July 6th. Finally, Raymond James Financial set a $220.00 target price on shares of DaVita in a research report on Friday, August 7th.

DaVita Stock Down 0.0%

Shares of NYSE:DVA opened at $187.22 on Tuesday. DaVita has a 12-month low of $101.00 and a 12-month high of $247.49. The stock has a market cap of $11.94 billion, a PE ratio of 15.32, a P/E/G ratio of 0.49 and a beta of 0.80. The business has a 50 day moving average of $180.54 and a 200-day moving average of $191.07.

DaVita (NYSE:DVA) last posted its earnings results on Tuesday, August 4th. The company reported $4.02 EPS for the quarter, beating the consensus estimate of $3.88 by $0.14. The company had revenue of $3.55 billion for the quarter, compared to the consensus estimate of $3.50 billion. DaVita had a negative return on equity of 217.63% and a net margin of 6.05%. The firm’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.95 earnings per share. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Equities research analysts expect that DaVita will post 14.57 earnings per share for the current year.

Institutional Trading of DaVita

Hedge funds and other institutional investors have recently bought and sold shares of the business. Value Investment Professionals LLC increased its position in shares of DaVita by 2.0% during the second quarter. Value Investment Professionals LLC now owns 2,501 shares of the company’s stock valued at $556,000 after acquiring an additional 50 shares in the last quarter. Kesler Norman & Wride LLC raised its holdings in DaVita by 0.8% in the 1st quarter. Kesler Norman & Wride LLC now owns 6,816 shares of the company’s stock worth $1,048,000 after acquiring an additional 55 shares during the last quarter. State of Alaska Department of Revenue lifted its position in DaVita by 1.9% in the 3rd quarter. State of Alaska Department of Revenue now owns 3,206 shares of the company’s stock valued at $560,000 after acquiring an additional 60 shares in the last quarter. Northwestern Mutual Wealth Management Co. lifted its position in DaVita by 4.1% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 1,915 shares of the company’s stock valued at $426,000 after acquiring an additional 76 shares in the last quarter. Finally, CoreCap Advisors LLC boosted its stake in DaVita by 161.7% during the 3rd quarter. CoreCap Advisors LLC now owns 157 shares of the company’s stock valued at $27,000 after purchasing an additional 97 shares during the last quarter. Institutional investors and hedge funds own 90.12% of the company’s stock.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a health care services company focused on kidney care. Through its DaVita Kidney Care business, the company provides outpatient dialysis treatments for people with chronic kidney failure, including in-center hemodialysis, home dialysis and related clinical support services.

DaVita also offers integrated kidney care programs intended to support patients across the stages of chronic kidney disease. Its services may include care coordination, disease management, education, transplant support and other services designed to improve clinical outcomes and help manage the needs of patients with complex kidney conditions.

The company operates a network of dialysis centers and related facilities in the United States and serves patients in select international markets.